Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Shijiazhuang Yiling Pharmaceutical identifies HIPK2 inhibitors

June 14, 2021

Iptacopan safely and effectively stabilizes eGFR in patients with C3 glomerulopathy

June 11, 2021

Nippon Shinyaku patents muscarinic acetylcholine M3 receptor positive allosteric modulators

June 9, 2021

BI-655064 does not meet CRR primary endpoint in lupus nephritis phase II trial

June 4, 2021

Pivotal study of venglustat in ADPKD stopped for futility

June 1, 2021

Targeting senescent cells restores kidney function

May 26, 2021

Regulus reports updated results from phase Ib study of RGLS-4326 in ADPKD

May 25, 2021

New phase Ib/IIa study evaluates VB-119 in membranous nephropathy

May 18, 2021

Dosing initiates in phase I study of GFB-024 in severe insulin-resistant diabetic nephropathy

May 14, 2021

Nephraegis Therapeutics to develop NPH-022 for the prevention and treatment of AKI

May 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...